Webinars

Past Webinars


microBrain™ is Back for Your Drug Discovery Needs! Featured Image

microBrain™ is Back for Your Drug Discovery Needs!

Speaker: AxoSim’s Newest Scientists Andrew LaCroix, PhD and Nicholas Coungeris | AxoSim Co-Founder and CEO J. Lowry Curley, PhD

Join us for a webinar: Functional screening on microBrain™ organoids and their applications to neuromodulation studies and disease modeling. With AxoSim’s acquisition of Vyant Bio’s StemoniX assets, the microBrain™ technology is back for your neuroscience preclinical research. Learn about the acquisition, this cutting edge technology and meet the talented scientists working exclusively with the platform.

View Webinar
ALS Awareness Month Webinar w/ Synapticure: Accelerating Care & Research for Neurological Diseases Featured Image

ALS Awareness Month Webinar w/ Synapticure: Accelerating Care & Research for Neurological Diseases

Speakers: Martina de Majo, PhD, Director or Research & Development at Synpaticure and Jaime Hatcher-Martin, MD, PhD, Movement Disorders Director Synapticure.

We’re honored to share that in recognition of ALS Awareness Month, AxoSim has invited the Synapticure team to highlight their incredible work in patient care and research for those living with ALS and other devastating neurodegenerative diseases.

Synapticure is creating a teleneurology hub where all patients diagnosed with ALS can have access to accurate information and resources to help them find the care and support they need to navigate their medical journey. Their patient-first approach with dedicated care coordinators for each patient, brings a human touch to a devastating diagnosis. They are also developing an extensive biobank of ALS patient samples to create powerful tools for researchers and drug developers, including patient-derived cells and organoids. In this webinar, Director of Research and Development Martina de Majo,PhD, and Director of Movement Disorders Jaime Hatcher-Martin, MD, PhD, will join us and take us through their work and what they are doing to accelerate research and care.

View Webinar
Human NerveSim®: A 3D In Vitro Nerve-on-a-Chip Model for Preclinical Drug Screening Featured Image

Human NerveSim®: A 3D In Vitro Nerve-on-a-Chip Model for Preclinical Drug Screening

Speaker: Megan Terral, Scientific Projects Manager, AxoSim

Preclinical animal models are historically expensive and low-throughput, and have largely failed to deliver results that translate to success in the human system. Peripheral nerves, in particular, lack predictive human-relevant in vitro drug screening models, with less than 7% of neurological drug candidates reaching the marketplace.

AxoSim has developed an all-human NerveSim® micro-physiological platform, using human iPSC-derived sensory neurons and primary human Schwann cells. This platform has been shown to exhibit crucial aspects of PN physiology and function, displaying robust neurite outgrowth, with axonal myelination and measurable electrical activity, acting as a promising screening platform for improving pre-clinical success.

About Megan

Megan is currently focused on demyelination and neuropathy studies at AxoSim. She received an undergraduate degree in biochemical engineering from the University of Georgia, where she grew interested in tissue engineering, biomaterials, and translational research.

*All times zones are Eastern Time*

 

View Webinar
“Human DRG studies on ectopic spontaneous activity” with Dr. Pat Dougherty of MD Anderson Featured Image

“Human DRG studies on ectopic spontaneous activity” with Dr. Pat Dougherty of MD Anderson

Speaker:  Patrick M Dougherty, Professor of Pain Medicine | MD Anderson Cancer Center

Take an in-depth look at Dr. Dougherty’s innovative research into neuropathic pain experienced by cancer patients.

For 22 years, Dr. Dougherty has held appointment as Professor of Pain Medicine at the University of Texas M.D. Anderson Cancer Center. His recent work centers on determining the mechanisms of neuropathic pain experienced by cancer patients. The work has been composed of parallel studies conducted in both humans and animals. In the human studies, he and his team have conducted psychophysical studies to define the sensory fibers involved in these pain conditions; and more recently, expanded this work to utilize human dorsal root ganglia tissue excised during surgical treatment for cancer. The animal studies have been to define both the peripheral and central neurophysiological mechanisms that are altered following cancer and cancer chemotherapy and to determine agents that may provide a neuroprotective role. The current emphasis in each of these studies is to determine the role that innate immune mechanisms play in the pathogenesis of cancer- and cancer treatment-evoked neuropathic pain.

*All times are Eastern Time Zone

View Webinar
1 2 3